Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154
RATIONALE: Studying samples of blood in the laboratory from patients before and after treatment may help doctors learn more about the effects of the treatment on cells.
PURPOSE: This clinical trial is studying samples collected from patients with localized prostate cancer who received treatment on clinical trial NCI-00-C-0154.
Procedure: diagnostic procedure
Procedure: molecular diagnostic method
Procedure: protein expression analysis
|Official Title:||Data Analysis for 00-C-0154, A Randomized Phase II Study of a PSA-based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy|
- Immunologic response
- Incidence of formation of antibody complexes in serum samples taken before initiation of treatment and after completion of therapy by western blot and SEREX
- Cloning of any underlying tumor antigens discovered in this process
|Study Completion Date:||March 2011|
- Evaluate the formation of antibody complexes in serum samples taken before initiation of treatment and after completion of therapy in prostate cancer patients previously enrolled on clinical trial NCI-00-C-0154.
- Evaluate immunologic response.
- Clone the underlying tumor antigens discovered through SEREX.
OUTLINE: Samples previously collected on clinical trial NCI-00-C-0154 (whole blood, serum, and peripheral mononuclear blood cells) are analyzed for immunologic responses and evidence of formation of anti-tumor antibodies. Western blot is used to detect any evidence of vaccine-induced autoantibody responses. If there is an indication of response, SEREX is used to clone the underlying antigens.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00535834
|Principal Investigator:||James Gulley, MD, PhD||National Cancer Institute (NCI)|